Endocrine Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Cortisol Test, Insulin Test, Others), By Technology (Tandem Mass Spectrometry, Immunoassay, Monoclonal & Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Endocrine Testing Market will grow from USD 2.81 Billion in 2024 to USD 4.69 Billion by 2030 at a 8.92% CAGR. Endocrine testing encompasses diagnostic procedures designed to evaluate the function of the endocrine system, which regulates essential hormonal balance throughout the body. These tests measure hormone levels in various biological samples to diagnose and monitor conditions such as diabetes, thyroid disorders, and adrenal insufficiency. The market's growth is primarily driven by the rising global prevalence of endocrine disorders, exemplified by diabetes, where according to the International Diabetes Federation, in 2024, approximately 589 million adults were living with diabetes worldwide. Additionally, increasing public awareness regarding preventive healthcare, coupled with government initiatives for early disease detection and continuous advancements in diagnostic technologies, further support market expansion.

These advancements include the development of highly sensitive assays and sophisticated automated platforms, enhancing diagnostic precision. However, a significant challenge impeding market expansion is the high cost associated with advanced testing technologies, which restricts their accessibility in developing regions and in smaller healthcare settings globally. This cost factor impacts widespread adoption despite the clear medical need.

Key Market Drivers

The rising prevalence of endocrine disorders fundamentally drives the demand for diagnostic solutions. Conditions such as thyroid dysfunction, diabetes, and adrenal insufficiencies are increasingly widespread globally, necessitating accurate and timely identification for effective management and improved patient outcomes. This escalating burden translates directly into a greater need for comprehensive endocrine testing. According to the American Thyroid Association, in 2025, over 12 percent of U.S. citizens may experience thyroid disease during their lifetime, underscoring a significant and persistent demand for related diagnostic interventions. The chronic nature of many endocrine conditions further ensures a continuous need for monitoring and reassessment throughout a patient's life, sustaining market activity.

Advancements in diagnostic technologies are profoundly shaping the endocrine testing market by enhancing accuracy, accessibility, and efficiency. Innovations range from highly sensitive assays and automated laboratory platforms to point-of-care and home-based testing solutions. These technological leaps make testing more convenient and less invasive, encouraging greater patient participation in screening and disease management. Exemplifying this progress, according to Athletech News, in February 2025, Level Zero Health secured $6.9 million in a pre-seed round for its continuous hormone monitoring wearable, demonstrating significant investment in novel, patient-centric diagnostic tools. The integration of advanced analytics, including artificial intelligence, also refines diagnostic precision by supporting complex hormonal data interpretation. Overall, the global endocrine testing market benefits from substantial institutional support for discovery; for instance, according to Northwestern Medicine's "2024 Milestones in Endocrinology: Advancing Research and Care" article, in June 2024, their endocrinology research program was backed by over $9 million in funding.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced testing technologies represents a significant impediment to the growth of the global endocrine testing market. This financial barrier directly restricts the widespread adoption of essential diagnostic procedures, particularly in developing regions where healthcare budgets are often limited. Smaller healthcare settings globally also face considerable challenges in acquiring and maintaining these expensive platforms, which consequently curtails their capacity to offer a comprehensive range of endocrine tests.

This cost-driven limitation on accessibility and adoption directly hampers market expansion, preventing a substantial portion of the global population from receiving timely and accurate diagnoses for prevalent endocrine conditions. For instance, according to the World Economic Forum, in 2024, 47% of the world's population lacked access to even the most basic diagnostics. This fundamental lack of access due to financial constraints slows market penetration, thereby impeding overall growth despite the clear and increasing medical need for endocrine diagnostics across diverse populations.

Key Market Trends

The growth of direct-to-consumer endocrine testing offerings is a significant market trend, enabling individuals to directly access diagnostic services without a traditional physician's referral. This paradigm shift democratizes access to health information, empowers patients in their wellness journeys, and fosters a proactive approach to health management. According to the American Diabetes Association's 2024 Annual Report, nearly 1 in 2 Americans has diabetes or prediabetes, collectively representing 136 million Americans living with these conditions. This substantial prevalence underscores the inherent demand for accessible diagnostic and monitoring tools, including those available through direct-to-consumer channels, for both early detection and ongoing health oversight. Illustrating this market development, Abbott launched its Lingo continuous glucose monitoring system in the U.S. in September 2024, a biosensor and mobile application designed for consumers aged 18 and older who do not use insulin, to track glucose in real-time for general wellness purposes.

The rising adoption of personalized and precision medicine approaches in endocrinology constitutes another pivotal trend, focusing on diagnostic and treatment strategies tailored to an individual’s unique genetic, lifestyle, and environmental factors. This advancement aims to enhance therapeutic efficacy and mitigate adverse drug reactions through more targeted interventions. The American Thyroid Association's 2025 Management Guidelines for Adult Patients with Differentiated Thyroid Cancer notably emphasize individualized care through a comprehensive DATA framework, seeking to enhance shared decision-making and personalize patient care. This formal endorsement from a leading industrial association signals the growing integration of personalized principles into clinical endocrinology. Further demonstrating this trajectory, Amylyx Pharmaceuticals presented new exploratory analyses from its Phase 2 clinical trials for avexitide, an investigational GLP-1 receptor antagonist for post-bariatric hypoglycemia, at the Endocrine Society’s annual meeting (ENDO 2025) in July 2025. This research into a targeted therapy for a specific metabolic complication exemplifies the ongoing shift toward highly individualized treatments.

Segmental Insights

Within the global endocrine testing market, the Thyroid Stimulating Hormone (TSH) Test segment is experiencing rapid growth, driven primarily by the escalating worldwide prevalence of thyroid disorders such as hypothyroidism and hyperthyroidism. Increased public and clinical awareness regarding thyroid health, coupled with a greater emphasis on early detection and management, has significantly boosted the demand for these crucial diagnostic tools. Moreover, continuous advancements in testing technologies have enhanced the accuracy, sensitivity, and accessibility of TSH tests, making them a preferred initial screening method in routine examinations. Global medical guidelines, including those from the American Thyroid Association, further reinforce TSH testing as a fundamental component of thyroid function assessment, thereby contributing to its sustained expansion.

Regional Insights

Europe is projected to maintain its leading position in the global endocrine testing market. This dominance is primarily driven by the region's robust and advanced healthcare infrastructure, coupled with a high prevalence of chronic endocrine disorders and reproductive health issues. Favorable government policies and comprehensive reimbursement schemes significantly bolster market expansion, promoting the adoption of advanced diagnostic technologies. The European Union's proactive regulatory framework, supported by institutions like the European Chemicals Agency and European Food Safety Agency, fosters a strong focus on endocrine health, including the identification and management of endocrine-disrupting substances. Additionally, the region's commitment to healthcare innovation and collaborative networks such as the EU Reference Network Rare Endocrine Conditions further contribute to its market leadership.

Recent Developments

• In January 2025, Abbott Laboratories received an innovation award for its Lingo system, a consumer biowearable device. This product, which emerged from the FreeStyle Libre continuous glucose monitoring technology, tracks glucose levels to deliver personalized insights for improving overall health and wellness. Showcased at CES 2025, this over-the-counter device represents a considerable step forward in personal health monitoring and preventative measures relevant to managing endocrine-related conditions such as diabetes.

• In December 2024, Roche received CE mark approval for its cobas® Mass Spec solution. This significant regulatory achievement encompassed the cobas® i 601 analyzer and the Ionify® reagent pack, which includes four specific assays designed for steroid hormones. This marked the initial phase of the global introduction for this automated, integrated, and standardized clinical mass spectrometry testing solution. The system is intended to enhance routine laboratory operations for endocrine diagnostics, with plans to expand its menu to a broader range of analytes.

• In June 2024, Thermo Fisher Scientific introduced the Thermo Scientific™ Stellar™ mass spectrometer. This new analytical instrument was designed to enhance precision medicine by combining rapid throughput with high sensitivity, thereby accelerating translational omics research. The Stellar mass spectrometer streamlines the verification of proteins and metabolites of clinical interest, significantly contributing to the discovery and validation of biomarkers. Its capabilities are particularly valuable for advancing various diagnostic fields, including the global endocrine testing market.

• In February 2024, research indicated that combining GLP-1 medicines with Abbott’s FreeStyle Libre system resulted in notable improvements in HbA1c levels for patients diagnosed with Type 2 diabetes. These findings highlight the enhanced effectiveness of integrating continuous glucose monitoring technology with pharmacological interventions. This represents a significant advancement in the management of diabetes, an endocrine disorder, and provides valuable insights for developing future endocrine testing strategies and patient care pathways.

Key Market Players

• Abbott Laboratories
• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• AB Sciex
• bioMerieux SA
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Ortho Clinical Diagnostics

Report Scope:

In this report, the Global Endocrine Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Endocrine Testing Market, By Test Type:

o   Estradiol (E2) Test

o   Follicle Stimulating Hormone (FSH) Test

o   Human Chorionic Gonadotropin (hCG) Hormone Test

o   Luteinizing Hormone (LH) Test

o   Dehydroepiandrosterone Sulfate (DHEAS) Test

o   Progesterone Test

o   Testosterone Test

o   Thyroid Stimulating Hormone (TSH) Test

o   Prolactin Test

o   Cortisol Test

o   Insulin Test

o   Others

• Endocrine Testing Market, By Technology:

o   Tandem Mass Spectrometry

o   Immunoassay

o   Monoclonal & Polyclonal Antibody Technologies

o   Sensor Technology

o   Clinical Chemistry

o   Others

• Endocrine Testing Market, By End user:

o   Hospitals & Clinics

o   Ambulatory Care Centers

o   Others

• Endocrine Testing Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Endocrine Testing Market.

Available Customizations:

Global Endocrine Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Endocrine Testing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]